IL2 and neuroblastoma: Moreover, the combination of another murine anti-GD2 antibody (ch14.G2a) with intravenous IL-2 showed a partial antitumor response in one neuroblastoma patient (out of 33 patients) and a decrease in neuroblastoma cells in the bone marrow of three patients [36].